These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Current Therapy and Liver Transplantation for Portopulmonary Hypertension in Japan. Tokushige K; Kogiso T; Egawa H J Clin Med; 2023 Jan; 12(2):. PubMed ID: 36675490 [TBL] [Abstract][Full Text] [Related]
23. Temporal Trends in Portopulmonary Hypertension Model for End-stage Liver Disease Exceptions and Outcomes. Del Valle KT; Krowka MJ; Heimbach JK; Taner T; DuBrock HM Transplant Direct; 2022 Dec; 8(12):e1410. PubMed ID: 36398194 [TBL] [Abstract][Full Text] [Related]
24. Congenital Absence of the Portal Vein as a Rare Cause of Portopulmonary Hypertension-A Case Study Series. Hlavata T; Kaldararova M; Klauco F; Drangova E; Reptova A; Simkova I Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295644 [No Abstract] [Full Text] [Related]
25. Unknown atrial septal defect was diagnosed during the course of treatment for portopulmonary hypertension: A case report. Kubota K; Miyanaga S; Iwatani N; Ohishi M J Cardiol Cases; 2022 Nov; 26(5):383-385. PubMed ID: 36312765 [TBL] [Abstract][Full Text] [Related]
30. Portopulmonary hypertension. Barua UK; Hossain AS; Roy GC; Rahman MA; Das M Mymensingh Med J; 2013 Jul; 22(3):618-24. PubMed ID: 23982562 [TBL] [Abstract][Full Text] [Related]
31. Portopulmonary hypertension. Al-Naamani N; Roberts KE Clin Chest Med; 2013 Dec; 34(4):719-37. PubMed ID: 24267301 [TBL] [Abstract][Full Text] [Related]
32. Bone Morphogenetic Protein 9 Is a Mechanistic Biomarker of Portopulmonary Hypertension. Nikolic I; Yung LM; Yang P; Malhotra R; Paskin-Flerlage SD; Dinter T; Bocobo GA; Tumelty KE; Faugno AJ; Troncone L; McNeil ME; Huang X; Coser KR; Lai CSC; Upton PD; Goumans MJ; Zamanian RT; Elliott CG; Lee A; Zheng W; Berasi SP; Huard C; Morrell NW; Chung RT; Channick RW; Roberts KE; Yu PB Am J Respir Crit Care Med; 2019 Apr; 199(7):891-902. PubMed ID: 30312106 [TBL] [Abstract][Full Text] [Related]
33. The Different Effects of Direct Bilirubin on Portopulmonary Hypertension and Idiopathic Pulmonary Arterial Hypertension. Li Y; Qiu H; Zhao Q; He J; Jiang R; Wu W; Luo C; Li H; Wang L; Liu J; Gong S Int J Clin Pract; 2022; 2022():7021178. PubMed ID: 35685569 [TBL] [Abstract][Full Text] [Related]
34. Current management approaches to portopulmonary hypertension. Savale L; O'Callaghan DS; Magnier R; Le Pavec J; Hervé P; Jaïs X; Seferian A; Humbert M; Simonneau G; Sitbon O Int J Clin Pract Suppl; 2011 Jan; (169):11-8. PubMed ID: 21176011 [TBL] [Abstract][Full Text] [Related]
35. Clinical Management and Outcomes of Patients With Portopulmonary Hypertension Enrolled in the Japanese Multicenter Registry. Tamura Y; Tamura Y; Taniguchi Y; Tsujino I; Inami T; Matsubara H; Shigeta A; Sugiyama Y; Adachi S; Abe K; Baba Y; Hatano M; Ikeda S; Kusunose K; Sugimura K; Usui S; Takeishi Y; Dohi K; Hasegawa-Tamba S; Horimoto K; Kikuchi N; Kumamaru H; Tatsumi K; Circ Rep; 2022 Nov; 4(11):542-549. PubMed ID: 36408361 [No Abstract] [Full Text] [Related]
36. Hepatopulmonary Syndrome and Portopulmonary Hypertension: Current Status and Implications for Liver Transplantation. Weinfurtner K; Forde K Curr Hepatol Rep; 2020 Sep; 19(3):174-185. PubMed ID: 32905452 [TBL] [Abstract][Full Text] [Related]